Concise Communication

Urinary tract infection stewardship: A urinary antibiogram and electronic medical record alert nudging narrower-spectrum antibiotics for urinary tract infections

Maryrose Laguio-Vila MD1, Mary L. Staicu PharmD2, Mary Lourdes Brundige PharmD2, Jose Alcantara MD3, Hongmei Yang PhD4, Ebbing Lautenbach MD5 and Ghinwa Dumyati MD6

1Department of Infectious Diseases, Rochester General Hospital, Rochester, New York, 2Department of Pharmacy, Rochester General Hospital, Rochester, New York, 3Department of Internal Medicine, Rochester General Hospital, Rochester, New York, 4Departments of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, 5Department of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania and 6Department of Infectious Diseases, University of Rochester Medical Center, Rochester, New York

Abstract

An antimicrobial stewardship intervention consisting of a urinary antibiogram and an electronic health record best-practice advisory promoted narrower-spectrum antibiotics for uncomplicated urinary tract infections in hospitalized patients. Over 20 months, the intervention significantly reduced ceftriaxone orders by 48% ($P < .001$) and increased cefazolin use 19 times from baseline ($P < .001$).

(Received 12 March 2021; accepted 23 April 2021)

Urinary tract infections (UTIs) are the second most common indication for inpatient antibiotics in the United States, making them a prime target for antimicrobial stewardship programs (ASPs). The 2010 Infectious Diseases Society of America guidelines for acute uncomplicated cystitis recommend narrow-spectrum antibiotics (NSAs), yet many hospitalized patients receive broad-spectrum antibiotics (BSAs). To reduce BSA use, such as third-generation cephalosporins, and to promote first-generation cephalosporin use for uncomplicated UTIs, we developed a urinary antibiogram and an electronic health record (EHR) best-practice advisory (BPA). We then measured their impact on antibiotic prescriptions for UTIs.

Methods

This single-center, quasi-experimental study was conducted in a 528-bed tertiary-care hospital in Rochester, New York. All antibiotics are ordered by computerized physician order entry in EHR software (Epic, Verona, WI) that includes a mandatory field for infectious indication. “Urinary tract infection” is 1 of 18 fields, encompassing both cystitis and pyelonephritis, regardless of infection severity. The ASP team prospectively receives 2 automated reports monthly: (1) antibiotic orders subcategorized by indication, and (2) days of therapy (DOT) without indication stratification. Support was provided by the Centers for Disease Control and Prevention Emerging Infection Program. The Rochester General Hospital Institutional Review Board approved this study and waived informed consent.

Intervention

The intervention involved 3 cephalosporins (ceftriaxone, cefazolin, and cephalexin) over 3 phases. From January 2016 through January 2018 (phase 0), monthly DOT and orders with UTI indication were prospectively calculated per 1,000 patient days. In collaboration with the microbiology laboratory, an inpatient urinary antibiogram of the most common urine pathogens of 2017 was created: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Enterococcus* spp. The laboratory introduced routine cefazolin Kirby-Bauer disc diffusion assays on urinary isolates for accurate susceptibility testing and release for clinical use (CLSI supplement M100, Wayne, PA). From February through July 2018 (phase 1), the ASP team gave lectures on the antibiogram and distributed a pocket reference card (Supplementary Material online). The ASP team also encouraged the application of the systemic inflammatory response syndrome (SIRS) criteria to identify potentially uncomplicated UTIs. Cases meeting 0–1 SIRS criteria were suggested to be low risk for negative outcomes and eligible for empiric NSA. Daily prospective audit of all new ceftriaxone orders identified additional cases eligible for NSA. In phase 2 (August 2018–October 2019), an EHR BPA designed by ASP with health informatics was introduced (Supplementary Material online). This BPA pop-up

Author for correspondence: Maryrose Laguio-Vila, MD, 1425 Portland Avenue Box 246, Rochester, New York 14621. E-mail: maryrose.laguiovila@rochesterregional.org

PREVIOUS PRESENTATION: These data were presented in poster form at IDWEEK 2019, on October 4, 2019, in Washington, DC.

Cite this article: Laguio-Vila M, et al. (2021). Urinary tract infection stewardship: A urinary antibiogram and electronic medical record alert nudging narrower-spectrum antibiotics for urinary tract infections. Antimicrobial Stewardship & Healthcare Epidemiology, https://doi.org/10.1017/ash.2021.163

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
window interrupted all providers ordering ceftriaxone with the UTI indication, explaining that ceftriaxone was a BSA and suggesting the use of NSAs according to the antibiogram. The primary outcome was changes in UTI treatments, measured as the number of ceftriaxone, cefazolin, and cephalexin orders for UTI per 1,000 patient days. Secondary outcomes were changes in each cephalosporin’s total DOT per 1,000 patient days.

**Analysis**

Negative binomial regression for data with overdispersion was applied to estimate and compare monthly cephalosporin-specific UTI orders and DOTs per 1,000 patient days among different study phases. We report rate ratios (RRs) and the corresponding 95% confidence intervals (CIs) after the interventions versus before the interventions. Interrupted time series (ITS) analysis by segmented regression models was used to assess the extent to which the interventions affected levels and trends in the rates of antibiotic UTI orders and DOT over the 3 phases of the intervention. The Durbin-Watson test was used to assess autocorrelation. Except where specified, all reported results compare phase 2 with phase 0. Analyses were conducted using SAS version 9.4 software (SAS Institute, Cary, NC).

**Results**

Rate ratios by negative binomial regression showed significant decreases in the rate of ceftriaxone UTI orders by Phase 2 (RR, 0.52; 95% CI, 0.48–0.55; P < .001) and in the rate of total ceftriaxone orders (RR, 0.87; 95% CI, 0.83–0.91; P < .001) (Table 1a). Conversely, there were significant increases in the rate of cefazolin UTI orders (RR, 19.59; 95% CI, 14.87–25.81; P < .001) and the rate of cefazolin DOT (RR, 1.13; 95% CI, 1.09–1.17; P < .001). We detected significant increases in the rates of cephalexin UTI orders (RR, 2.43; 95% CI, 2.11–2.79; P < .001), cephalexin total orders (RR, 1.18; 95% CI, 1.08–1.30; P < .001), and cephalexin DOT (RR, 1.32; 95% CI, 1.21–1.44; P < .001).

By ITS, a significant decrease in the levels of ceftriaxone UTI orders (level change, 5.61; P = .001), total orders (level change, −9.38; P < .001), and DOT (level change, −14.87; P < .001) occurred from phase 0 to phase 2 (Fig. 1 and Table 1b). A significant increase in the level of cefazolin UTI orders also occurred without changes in the levels of cefazolin total orders or DOT. Significant increases in the levels of cephalexin UTI orders and DOT also occurred. The results of the Durbin-Watson test suggested no indication for autocorrelation in the study data, which was confirmed by residual plots.

**Discussion**

This intervention significantly reduced ceftriaxone ordering by 48% while increasing cefazolin and cephalexin prescribing by 19 times and 2.4 times over the baseline, respectively. Previously, cefazolin was not commonly prescribed for UTIs of any severity in our institution. Thus, collaboration with the microbiology laboratory was integral to creating a urinary antibiogram demonstrating high local NSA susceptibility to facilitate provider buy-in. The use of institution-specific syndromic antibiograms may provide more accurate estimates of resistance and greater potential to better guide empiric treatment.

**Table 1a. Antibiotic Use Rate Ratios by Urinary Tract Infection (UTI) Antibiotic Orders and Total Antibiotic Days of Therapy by Phase of Intervention**

| Antimicrobial Agent | Phase 0 | Phase 1 | Phase 2 |
|---------------------|---------|---------|---------|
| Ceftriaxone Orders/Patient Days Rate | 6,944/621,746 | 102,822,746 | 102,822,746 |
| Ceftriaxone DOT | 29,983/621,746 | 29,983/621,746 | 29,983/621,746 |
| Cefazolin Orders/Patient Days Rate | 202/621,746 | 102,822,746 | 102,822,746 |
| Cefazolin DOT | 47,177,621,746 | 47,177,621,746 | 47,177,621,746 |
| Cephalexin Orders/Patient Days Rate | 1,172/121,363 | 1,172/121,363 | 1,172/121,363 |
| Cephalexin DOT | 6,699,121,363 | 6,699,121,363 | 6,699,121,363 |

Note. RR, rate ratio; LCL, lower confidence limit; UCL, upper confidence limit.

*Rate estimated with negative binomial regression.

**Table 1b. Antibiotic Use Rate Ratios by Phase and Total Antibiotic Days of Therapy**

| Antimicrobial Agent | Phase | Total Antibiotic Days of Therapy |
|---------------------|-------|---------------------------------|
| Ceftriaxone DOT | 5,76/621,746 | 5,76/621,746 |
| Cefazolin DOT | 1,954/621,746 | 1,954/621,746 |
| Cephalexin DOT | 75,86/621,746 | 75,86/621,746 |
Fig. 1. Changes in urinary tract infection (UTI) antibiotic orders (left) and total days of therapy (DOT) per 1,000 patient days (right) associated with implementation of a urinary antibiogram (phase 1) and an electronic medical record best practice advisory (phase 2).
consistent with national guidelines; however, local prescriber concerns for low potency and adverse events, and practices preferring intravenous antibiotics for hospitalized patients precluded this step. Local ASPs and their associated laboratories could explore other NSAs and tailor recommendations accordingly.

ASP teams can leverage the customizability of the EHR to efficiently target prescribers at optimal times and with specific information to guide clinical decision making. This BPA was designed to reach providers at the final moment of ceftriaxone prescribing and to reinforce ASP principles. We observed that education in phase 1 significantly influenced cefazolin orders but with minimal changes in ceftriaxone orders. However, significant changes in ceftriaxone ordering materialized in phase 2, likely due to the BPA.

The impact on total NSA DOT was modest, with no significant change in total ceftriaxone DOT. This finding was expected because UTIs represent only a portion of infectious indications. Prior to this intervention, >95% of cefazolin orders were for surgical prophylaxis, diluting any subsequent changes in cefazolin metrics. Similarly, ceftriaxone DOT was likely confounded by the concomitant national ampicillin-sulbactam shortage, which diverted many regimens to include ceftriaxone.

Sociobehavioral studies suggest that stewardship interventions that do not interfere with workflow or negatively affect efficiency may be more readily accepted. In this intervention, we deliberately incorporated the widely used SIRS criteria into antibiotic decision making. The intent was to bolster prescriber confidence that each case with low SIRS criteria was low risk for negative clinical outcomes should an NSA provide inadequate bacterial coverage. Secondarily, it cognitively links the intervention to a process embedded in provider workflow. We are unaware of other studies using SIRS criteria in a stewardship strategy.

This study has several limitations. The high susceptibility of urinary pathogens to these NSAs may not be widely applicable. However, collaboration with microbiology to identify local NSAs could be replicated. Second, because the BPA is UTI specific, providers determined to order ceftriaxone potentially could achieve a “workaround” by choosing non-UTI indications, leading to falsely low measurement of ceftriaxone UTI orders. Last, the study did not assess clinical outcomes such as NSA effectiveness and safety. This aspect will be a focus of future investigations.

In conclusion, a multimodal syndromic stewardship intervention introducing a urinary antibiogram and a BPA significantly reduced ceftriaxone and successfully increased NSAs for UTI treatments in hospitalized patients.

**Supplementary material.** To view supplementary material for this article, please visit https://doi.org/10.1017/ash.2021.163

**Acknowledgments.** The authors thank the members of the Targeted Restriction of Antimicrobials to Prevent Clostridium difficile Infection (TRAP-CDEI) study group, including Scott Fridkin, Mary Beth Sexton, Hasan Shabbir, Zanthia Wiley, Ray Dantes, Julianne Kubes, Chad Robichaux, Ashley Jones, Keith Hamilton, Brendan Kelly, Brandi Muller, Julie Szmyczak, Anne Jaskowiak, Jeff Gerber, Erik Dubberke, Alice Guh, Sujan Reddy, Laurie Hicks, John Jernigan, Tiffanee Woodard, Melinda Neuhauser, and Maria Karlsson.

**Financial support.** This work was supported by the Centers for Diseases Control and Prevention Emerging Infections Program.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**References**

1. Magill SS, Edwards JR, Beldavs ZG, et al. Prevalence of antimicrobial use in US acute-care hospitals, May–September 2011. JAMA 2014;312:1438–1446.

2. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103–e120.

3. Wick J, Beaulac K, Doron S. Evaluation of a healthcare-associated urinary tract infection combination antibiogram. Infect Control Hosp Epidemiol 2016;37:1101–1104.

4. Hebert C, Ridgway J, Vekhter B, Brown EC, Weber SG, Robicsek A. Demonstration of the weighted-incidence syndromic combination antibiogram: an empiric prescribing decision aid. Infect Control Hosp Epidemiol 2012;33:381–388.

5. Forrest GN, Van Schooneveld TC, Kollar R, Schulz IT, Duong P, Postelnick M. Use of electronic health records and clinical decision support systems for antimicrobial stewardship. Clin Infect Dis 2014;59:S122–S133.

6. Szmyczak JE, Kitt E, Hayes M, et al. Threatened efficiency not autonomy: prescriber perceptions of an established pediatric antimicrobial stewardship program. Infect Control Hosp Epidemiol 2019;40:522–527.

**Table 1b. Changes in Levels and Trends in Antibiotic Use per 1,000 Patient Days by Segmented Regression Analysis of Interrupted Time Series From Phase 0 to Phase 2**

| Antimicrobial Agent | Change in Level | Standard Error | Pr > |t| | Level Change From Phase 0, % | Change in Trend | Standard Error | Pr > |t| |
|--------------------|----------------|---------------|------|-------|------------------------|----------------|---------------|------|-------|
| Ceftriaxone         |                |               |      |       |                        |                |               |      |       |
| UTI orders         | −5.61          | 0.97          | <.001 |       | −47                    | −0.10          | 0.07          | .133 |
| Total orders        | −9.38          | 2.02          | <.001 |       | −24                    | −0.12          | 0.14          | .370 |
| DOT                | −14.87         | 3.48          | <.001 |       | −29                    | 0.64           | 0.23          | .009 |
| Cefazolin           |                |               |      |       |                        |                |               |      |       |
| UTI orders         | 1.19           | 0.41          | .006 | 570   | 0.13                   | 0.03           | <.001         |      |
| Total orders        | −11.01         | 6.19          | .083 | −8    | −0.67                  | 0.42           | .114          |      |
| DOT                | −3.31          | 3.59          | .363 | −4    | 0.69                   | 0.24           | .007          |      |
| Cephalexin          |                |               |      |       |                        |                |               |      |       |
| UTI orders         | 1.66           | 0.41          | <.001 | 115   | 0.01                   | 0.03           | .680          |      |
| Total orders        | 1.47           | 1.32          | .272 | 17    | 0.06                   | 0.09           | .489          |      |
| DOT                | 3.80           | 1.61          | .023 | 34    | 0.06                   | 0.11           | .595          |      |

Note. UTI, urinary tract infection; DOT, days of therapy.

**P** value for the |t| test. Bold indicates statistical significance.